Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones

Atherosclerosis

Volumn 169, Issue 2, 2003, Pages 235-243

  Game, Bryan A ^a   Xu, Minfu ^a   Lopes Virella, Maria F ^a,b   Huang, Yan ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diabetes; Gene expression; Interstitial collagenase; Matrix metalloproteinases; PPAR

Indexed keywords

ANTIDIABETIC AGENT; CYSTEINE; INITIATION FACTOR 4E; INITIATION FACTOR 4G; INSULIN; INTERSTITIAL COLLAGENASE; MESSENGER RNA; METHIONINE; PIOGLITAZONE; ROSIGLITAZONE; SULFUR 35; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TROGLITAZONE;

AORTA; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME RELEASE; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; INSULIN SENSITIVITY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOASSAY; TRANSLATION INITIATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 0142092675     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00165-5     Document Type: Conference Paper

References (43)

1. Satiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
2. Suter S.L., Nolan J.J., Wallace P., Gumbiner B., Olefsky J.M. Metabolic effect of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:1992;193-203.
3. Maggs D.G., Buchanan T.A., Burant C.F., Cline G., Gumbiner B., Hsueh W.A., Inzucchi S., Kelley D., Nolan J., Olefsky J.M., Polonsky K.S., Silver D., Valiquett T.R., Shulman G.I. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double blind, placebo-controlled trial. Ann. Intern. Med. 128:1998;176-185.
4. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., Olefsky J.M. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl. J. Med. 331:1994;1188-1193.
5. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Wilson T.M., Kliewer S.A. An antidiabetic thiazollidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor γ (PPAR-γ). J. Biol. Chem. 270:1995;12953-12956.
6. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37:1996;907-925.
7. Lemerger T., Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Ann. Rev. Cell Dev. Biol. 12:1996;335-363.
8. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-γ Cell. 83:1995;803-812.
9. Gaba M.K., Gaba S., Clark L.T. Cardiovascular disease in patients with diabetes: clinical consideration. J. Assoc. Acad. Minorit. Physicians. 10:1999;15-22.
10. Nagy L., Tontonoz P., Alvarez J.G.A., Chen H., Evans R.M. Oxidized LDL regulates macrophages gene expression through ligand activation of PPAR-γ Cell. 93:1998;229-240.
11. Marx N., Schonbeck U., Lazar M.A., Libby P., Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83:1998;1097-1103.
12. Marx N., Bourcier T., Sukhova G.K., Libby P., Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression. PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19:1999;546-551.
13. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 129:2000;823-834.
14. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-g is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
15. Lee H., Shi W., Tontonoz P., Wang S., Subbanagounder G., Hedrick C.C., Hama S., Borromeo C., Evans R.M., Berliner J.A., Nagy L. Role for peroxisome proliferator-activated receptor-γ alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ. Res. 87:2000;516-521.
16. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
17. Davies M.J., Richardson P.C., Wooolf N., Katz D.R., Mann J. Risk of thrombosis in human atherosclerotic plaques: role of atherosclerotic plaques. Lancet. 2:1989;941-944.
18. Richard P.D., Davies M.J., Born G.V.R. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 2:1989;941-944.
19. Burleigh M.C., Briggs A.D., Lendon C.L., Davies M.J., Born G.V., Richardson P.D. Collagen type I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations. Atherosclerosis. 96:1992;71-81.
20. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
21. Matrisian L.M. The matrix-degrading metalloproteinases. BioEssays. 14:1992;455-463.
22. Galis Z.S., Suknova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:1995;2493-2503.
23. Morton L.F., Barnes M.J. Collagen polymorphism in the normal and diseased blood vessel wall. Investigation of collagens types I, III and V. Atherosclerosis. 42:1982;41-51.
24. Hanson A.N., Bentley J.P. Quantitation of type I to type III collagen ratios in small samples of human tendon, blood vessels, and atherosclerotic plaques. Anal. Biochem. 130:1983;32-40.
25. McCarthy M.J., Loftus I.M., Thompson M.M., Jones L., London N.J., Bell P.R., Naylor A.R., Brindle N.P. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J. Vasc. Surg. 30:1999;261-268.
26. Huang Y., Mironova M., Lopes-Virella M.F. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19:1999;2640-2647.
27. Davis G.F., Khandelwal R.L., Wu L., Juurlink B.H., Roesler W.J. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPAR gamma)-independent, antioxidant-related mechanism. Biochem. Pharmacol. 62:2001;1071-1079.
28. Marra F., DeFranco R., Grappone C., Parola M., Milani S., Leonarduzzi G., Pastacaldi S., Wenzel U.O., Pinzani M., Dianzani M.U., Laffi G., Gentilini P. Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J. Invest. Med. 47:1999;66-75.
29. Keiper B.D., Gan W., Rhoads R.E. Protein synthesis initiation factor 4G. Int. J. Biochem. Cell Biol. 31:1999;37-41.
30. Marx N., Sukhova G., Murphy C., Libby P., Plutzky J. Macrophages in human atheroma contain PPARγ: differentiation-dependent PPARγ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes. Am. J. Pathol. 153:1998;17-23.
31. Shu H., Wong B., Zhou G., Li Y., Berger J., Woods J.W., Wright S.D., Cai T.O. Activation of PPAR alpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem. Biophys. Res. Commun. 267:2000;345-349.
32. Neve B.P., Fruchart J., Staels B. Role of the peroxisome proliferator-activated receptor (PPAR) in atherosclerosis. Biochem. Pharmacol. 60:2000;1245-1250.
33. Mudaliar S., Henry R.R. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu. Rev. Med. 52:2001;239-257.
34. Hattori Y., Akimoto K., Kasai K. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem. Biophys. Res. Commun. 273:2000;1144-1149.
35. Yamazaki H., Suzuki M., Tane K., Shimada N., Nakajima M., Yokoi T. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 30:2000;61-70.
36. Knock G.A., Mishra S.K., Aaronson P.I. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur. J. Pharmacol. 368:1999;103-109.
37. Xu M., Game B.A., Lopes-Virella M.F., Huang Y. Insulin sensitizer troglitazone stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Diabetes. 50:(Suppl. 2):2000;690.
38. Fazzio A., Marilley D., Azzi A. The effect of alpha-tocopherol on proliferation, protein kinase C activity and gene expression in different cell lines. Biochem. Mol. Biol. Int. 41:1997;93-101.
39. Cominacini L., Young M.M., Capriati A., Garbin U., Fratta Pasini A., Campagnola M., Davoli A., Rigoni A., Contessi G.B., Lo Cascio V. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia. 40:1997;1211-1218.
40. Loi C., Young M., Randinitis E., Vassos A., Koup J.R. Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet. 37:1999;91-104.
41. Gingras A., Raught B., Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68:1999;913-963.
42. Raught B., Gingras A. eIF4E activity is regulated at multiple levels. Int. J. Biochem. Cell. Biol. 31:1999;43-57.
43. Kawai K., Kawasaki-Tokui Y., Odaka T., Tsuruta F., Kazui M., Iwabuchi H., Nakamura T., Kinoshita T., Ikeda T., Yoshioka T., Komai T., Nakamura K. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimettel Forschung. 47:1997;356-368.